BALAXI PHARMACEUTICALS LIMITED — Board Meeting, 28-05-2026: Outcome of Board Meeting

Balaxi Pharma's Board approved FY26 consolidated results (Revenue ₹270.17 Cr, Net Profit ₹1.42 Cr). It secured a manufacturing license for its Jadcherla plant, now set for commercialization of key products. Internal auditors were re-appointed, and an independent director's re-appointment was proposed.